PNX’s mechanism of action offers several avenues for therapeutic exploitation in the management of obesity, appetite dysregulation, and diabetes in cats and dogs (Figure 2). The gene discussed is SMIM20; the disease is obesity due to melanocortin 4 receptor deficiency.